Related coverage linked through entity extraction aliases.
Apr 06, 2026
JAMA Neurology published Phase 2b PARADIGM results for PrimeC in ALS, showing slower functional decline, fewer ALS-related complications and longer survival. NeuroSense is preparing a Phase 3 trial and received Brazilian patent protection through October 2042.
Apr 05, 2026
Researchers used machine learning to identify an antimicrobial peptide, LR, that reduced inflammation and improved gut barrier function in mouse ulcerative colitis. The peptide also reshaped the microbiome and outperformed 5-aminosalicylic acid and ciprofloxacin in the model.
Mar 16, 2026
PrimeC, an oral combination therapy, showed safety and signals of clinical benefit in a phase 2b trial, while PLL001, a gut-targeting therapy, demonstrated positive safety and tolerability in a phase I/II study for amyotrophic lateral sclerosis.
Feb 18, 2026
A joint report from the European Food Safety Authority and the European Centre for Disease Prevention and Control finds antimicrobial resistance in Salmonella and Campylobacter continues to pose a public health concern across Europe, though several countries have reported progress in reducing resistance levels.
Feb 14, 2026
The CDC is investigating a multistate outbreak of extensively drug-resistant Salmonella Newport with an NDM-1 gene linked to Rosabella moringa powder capsules, marking the first documented outbreak of Salmonella with an NDM-1 gene in the United States.
Feb 13, 2026
CDC and FDA are investigating a multistate outbreak of extensively drug-resistant Salmonella Newport infections linked to Rosabella brand moringa powder capsules, with seven people sickened across seven states and three requiring hospitalization.
